jnj-61393215
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02812251)
Timeline
Indications
Mechanism of action
- Orexin receptor 1ANTAGONIST
HCRTR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj-61393215
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04713930 | Phase 1 | Jan 29, 2021 | Janssen Pharmaceutica NV |
| NCT04080752 | Phase 2 | Sep 17, 2019 | Janssen Pharmaceutica NV |
| NCT03649997 | Phase 1 | Aug 28, 2018 | Johnson and Johnson |
| NCT03593954 | Phase 1 | Jul 31, 2018 | Johnson and Johnson |
| NCT03007693 | Phase 1 | Jan 1, 2017 | Johnson and Johnson |
| NCT02812251 | Phase 1 | Jul 1, 2016 | Johnson and Johnson |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 4 | 4 | 1 | 2016 |
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 2 | 2019 |
2 organizations
Page 1 / 1